Le Lézard
Classified in: Business
Subject: PER

Bertram Capital Promotes Tim Heston to Partner


SAN MATEO, Calif., Oct. 18, 2018 /PRNewswire/ -- Bertram Capital ("Bertram"), a middle market private equity firm, is pleased to announce the promotion of Tim Heston to Partner. Mr. Heston, previously a Principal at Bertram, has been with the firm for more than 10 years and focuses his efforts on executing and managing portfolio company investments in the industrial/manufacturing sector.

Tim Heston has played an integral role in building Bertram's industrial/manufacturing investment practice.  In 2018, Mr. Heston helped lead the successful sale and served on the Board of Directors of five Bertram portfolio companies: Clarus Glassboards (brand writable glassboards), Maxcess (web handling solutions), Rowmark (engravable plastic sheet) and Premier Material Concepts (engineered plastic sheet).  Mr. Heston previously served on the Board of Directors for exited portfolio company EDI Holdings, Inc. (extrusion die manufacturer) and was a key contributor to the growth and subsequent exit of Bertram portfolio company Power Distribution, Inc

"I am pleased to announce Tim Heston's well-deserved promotion to Partner," said Jeff Drazan, Managing Partner at Bertram Capital. "Tim has selflessly dedicated his efforts to building our firm and helping to create our industrial/manufacturing sector investment platform.  Tim played an integral role in every industrial/manufacturing company in which we have invested and his promotion to Partner is a direct result of these contributions."

Mr. Heston joined Bertram in the summer of 2008 as a summer intern while attending Haas Graduate School at the University of California at Berkeley.  Prior to joining Bertram, Mr. Heston worked at Calera Capital where he evaluated investment opportunities across a diverse range of industries.  Additionally, Mr. Heston was a member of the Mergers & Acquisitions group at J.P. Morgan and the Investment Banking group at Carl Marks & Co.

About Bertram Capital
Bertram Capital is a private equity firm with over $1.4 billion in committed capital targeting investments in lower middle market companies.  In addition to supplying strategic growth capital, Bertram Capital leverages proprietary processes and services, Bertram High-5SM and Bertram Labs, to empower its portfolio companies to unlock their full business potential. The Bertram High-5SM is an operationally-focused value creation strategy, which includes management augmentation, operational initiative implementation, complimentary business acquisition, sales and marketing improvements and leveraging technology and IP.  The cornerstone of this strategy is Bertram Labs, its in-house technology team, which drives growth and value through digital marketing, e-commerce, big data and analytics, application development and internal and external platform optimization. Visit www.bertramcapital.com for more information.

 

Bertram Capital. (PRNewsFoto/Bertram Capital)

SOURCE Bertram Capital


These press releases may also interest you

at 10:00
Gilbane Building Company is proud to be a founding member of Construction Inclusion Week (CIW) and to join the industry to mark its fourth year promoting inclusion and belonging through the weeklong event. This year's event, taking place from October...

at 09:30
Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bumble Inc. between November 7, 2023 and August 7, 2024, both dates inclusive (the "Class Period"), of the important November 25, 2024 lead plaintiff...

at 08:27
Akeso Biopharma (9926. HK) ("Akeso", the "Company" ) announced that it has successfully raised approximately $250 million USD through a share placement. This offering has earned notable recognition among international investment firms, with the...

at 08:00
Gate Ventures, a global venture capital firm specializing in blockchain; Movement Labs, a leader in Move-based blockchain technology; and Boon Ventures, a prominent investor in emerging tech startups, today announced the establishment of a...

at 04:04
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration...

at 03:47
The 90th China International Medical Equipment Fair (CMEF) has successfully kicked off in Shenzhen, running from October 12-15. This year's event spans nearly 200,000 square meters and hosts nearly 4,000 exhibitors with an audience surpassing 200,000...



News published on and distributed by: